Advancements in preeclampsia: innovative screening methods and effective prevention strategies

 Progrese în managementul preeclampsiei: metode noi de screening şi strategii eficiente de prevenţie

First published: 30 mai 2024

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Gine.44.2.2024.9668


Preeclampsia, affecting 5-10% of pregnancies, is a major cause of maternal and fetal morbidity and mortality, cha­rac­te­rized by elevated blood pressure and proteinuria after 20 weeks of gestation. The complications include in­tra­ute­rine growth restriction, eclampsia, placental abruption, and HELLP syndrome. Effective first-trimester screening, re­com­men­ded by international societies, considers maternal risk fac­tors such as the PlGF (placental growth factor) value, the pulsatility index of the uterine arteries, and the mean blood pressure. Advances in soluble biomarkers, especially the sFlt-1/PlGF ratio, offer improved early diagnosis and ma­nage­ment by predicting preeclampsia weeks before the symp­toms appear. Preventive measures – notably, low-dose as­pi­rin – have been validated by the ASPRE study, showing a 62% reduction in preterm preeclampsia risk when ad­mi­nis­tered from 11-14 weeks of gestation. Implementing these scre­ening and prevention strategies nationwide, especially in resource-limited areas, is essential to reduce the incidence and to improve the outcomes for mothers and babies.

preeclampsia, screening, prevention, aspirin, PlGF, sFlt1


Preeclampsia, afectând 5-10% din sarcini, este o cauză ma­jo­ră de morbiditate şi mortalitate maternă şi fetală, fiind ca­rac­te­ri­za­tă prin valori crescute ale tensiunii arteriale şi proteinurie de­ce­la­te după 20 de săptămâni de gestaţie. Complicaţiile in­­clud restricţia de creştere intrauterină, eclampsia, dezlipirea pre­­ma­tu­ră de placentă normal inserată şi sindromul HELLP. Scre­e­nin­gul eficient în primul trimestru, recomandat de societăţile in­ter­na­ţio­na­le, ia în considerare factori de risc materni precum va­­loa­rea PlGF (placental growth factor), indexul de pulsatilitate al arterelor uterine şi tensiunea arterială medie. Progresele în uti­li­za­rea biomarkerilor solubili, în special raportul sFlt-1/PlGF, ofe­ră un diagnostic şi o gestionare îmbunătăţite, prin predicţia pre­eclamp­si­ei cu săptămâni înainte de apariţia simptomelor. Mă­­su­ri­le preventive, în special administrarea de aspirină în do­ză mi­că, au fost validate de studiul ASPRE, arătând o reducere cu 62% a riscului de preeclampsie cu debut precoce atunci când este administrată între 11 şi 14 săptămâni de gestaţie. Im­ple­men­ta­rea acestor strategii de screening şi prevenţie la nivel na­ţio­nal, în special în zonele cu resurse limitate, este esenţială pen­tru a reduce incidenţa şi a îmbunătăţi prognosticul pentru ma­me şi nou-născuţi.


Preeclampsia is a condition that affects 5-10% of pregnancies, being considered a systemic vascular dysfunction that is characterized by proteinuria and increased blood pressure values. The complications of preeclampsia include intrauterine growth restriction, convulsions (eclampsia), placental abruption, and an association that includes hemolysis, elevated transaminases and thrombocytopenia (HELLP syndrome). The manifestations of preeclampsia disappear after birth, the obstetrical solving being the only effective treatment of preeclampsia. However, a history of preeclampsia is associated with an increased cardiovascular risk throughout life(1).

The diagnosis of preeclampsia is made when there is an increase in blood pressure above 140/90 mmHg associated with a value of proteinuria/24 hours above 300 mg/24 hours, or when the urinary protein/creatinine ratio is above 0.3, or when the urine dipstick test result is +1, manifestations that appear after 20 weeks of gestation. In the absence of proteinuria, the diagnosis can be made when there are manifestations such as pulmonary edema, thrombocytopenia, liver or kidney damage(2).

Preeclampsia screening

The National Institute for Health and Care Excellence (NICE)(3), the American College of Obstetricians and Gynecologists (ACOG)(4) and the International Society for the Study of Hypertension in Pregnancy (ISSHP)(5) advocate for screening pregnant women for preeclampsia (PE) during the first trimester. This screening is recommended based on various maternal risk factors which include: interpregnancy interval exceeding 10 years, family history of preeclampsia, factors related to the pregnancy itself, such as nulliparity, multiple pregnancy, or conception through assisted reproductive technology, chronic hypertension or kidney disease, previous occurrence of preeclampsia or hypertension during pregnancy, maternal age of 35 years old or above, a pre-pregnancy Body Mass Index exceeding 30 kg/m2, or pre-pregnancy conditions like diabetes mellitus or autoimmune diseases. These organizations also suggest that women at a high risk of preeclampsia be offered low-dose aspirin as a preventive measure against the onset of preeclampsia. The administration of aspirin before 16 weeks of pregnancy to women at a high risk of developing preeclampsia has been shown to be effective in reducing this risk. Therefore, the development of prediction methods for this condition represents an important area of research in the medical field(6).

Soluble fms-like tyrosine kinase 1 (sFlt-1), an antiangiogenic factor crucial for regulating angiogenic balance during pregnancy, plays a pivotal role(7). Typically, its concentration rises steadily during the third trimester of normal pregnancy. However, in women who later develop preeclampsia (PE) or experience pregnancy complicated by fetal growth restriction (FGR), sFlt-1 levels elevate prematurely(8). Maternal levels of circulating sFlt-1 have been observed to increase approximately five weeks before the onset of symptoms(8). sFlt-1 binds to PlGF, and recent research indicates that the excess circulating sFlt-1 largely mediates the decreased levels of PlGF(9). PlGF – a proangiogenic factor expressed in the placenta – aids in the action of vascular endothelial growth factor-A (VEGF-A), vital for placental vascular development(7). Initially, maternal PlGF concentration rises, peaks around mid-gestation, and then gradually decreases towards term(8,10). However, this decline in PlGF concentration occurs prematurely in women who later develop PE, often detectable before the symptom onset(11). The elevation of sFlt-1 levels and the decrease in PlGF levels lead to an increased sFlt-1/PlGF ratio. Consequently, this ratio serves as a valuable tool for predicting and/or diagnosing placenta-related disorders, including preeclampsia, FGR, stillbirth, and preterm birth(12). While other antiangiogenic factors like VEGF-A and soluble endoglin have been explored as biomarkers for diagnosing and predicting preeclampsia, they have not yet been integrated into clinical practice due to their limited additional value(8,13).

In the first trimester, the preeclampsia predictive value of sFlt1 and PlGF was extensively researched. Although no correlation was established between the sFlt1 level and the occurrence of preeclampsia in the first trimester, the value of PlGF proved to be a good predictor of the development of preeclampsia(14,15). Compared to the conventional method of evaluating maternal risk factors for the prediction of preeclampsia, a new method consisting of an algorithm that combines maternal factors, the PlGF value, the pulsatility index of the uterine arteries and the mean blood pressure, proved to be clearly superior(16). The ASPRE study demonstrated that the administration of aspirin in high-risk patients identified using this algorithm significantly reduced the risk of preterm preeclampsia(17).

In the second and third trimesters, for women suspected of having preeclampsia, the sFlt1/PlGF ratio demonstrates a notably high negative predictive value for excluding the onset of preeclampsia within seven days(18), adverse maternal outcomes within 14 days(19), or delivery with preeclampsia within 14 days(18). Various thresholds for the sFlt-1/PlGF ratio have been determined through ROC-curve analysis. Verlohren et al. validated a series of gestational-age-dependent thresholds for diagnosing preeclampsia. For early-onset PE (<34 weeks of gestation), an sFlt-1/PlGF ratio ≤33 effectively ruled out preeclampsia at the time of testing, with a sensitivity of 95% and a specificity of 94.0%. Conversely, an sFlt-1/PlGF ratio ≥85 diagnosed preeclampsia with a sensitivity of 88% and a specificity of 99.5%. For late-onset PE (≥34 weeks of gestation), an sFlt-1/PlGF ratio ≤33 ruled out preeclampsia at the time of testing with a sensitivity of 89.6% and a specificity of 73.1%. Conversely, an sFlt-1/PlGF ratio ≥110 diagnosed PE with a sensitivity of 58.2% and a specificity of 95.5%(20). Herraiz et al. reported that using an sFlt-1/PlGF ratio cutoff >95th percentile at 24-28 weeks of gestation identified 100% of women at high risk of preeclampsia, who subsequently developed the early-onset form of the disease, in a prospective observational study of 5601 pregnant women(21).

Prevention of preeclampsia

The effects of aspirin consist of an anti-inflammatory, analgesic and antipyretic effect, this drug being part of the class of nonsteroidal anti-inflammatory drugs. The mechanism of action of aspirin consists in the inhibition of cyclooxygenase COX-1 and COX-2, which causes a decrease in prostaglandins and thromboxane. The decrease in thromboxane has an antithrombotic effect by decreasing platelet aggregation(22,23). Recently, new evidence has suggested that in the etiology of preeclampsia a deficient trophoblastic invasion would be involved, which causes a discordance between angiogenic and antiangiogenic factors, this leading to inflammation and systemic vascular damage, following an increase in platelet aggregation, with thrombotic events and placental infarcts(24). Thus, the hypothesis was raised that aspirin, through its effects, would be a good medicinal agent to reduce the risk of preeclampsia(25).

Numerous studies have evaluated the role of aspirin in the prevention of preeclampsia, but with contradictory results, considering the various definitions of the pathology used in the studies, the different doses in which aspirin was administered, as well as the gestational age at which the treatment was started(26). Therefore, to establish the effectiveness of aspirin in the prevention of preeclampsia, the ASPRE study was carried out. In this study, high-risk women received aspirin starting with 11-14 weeks of pregnancy, in a dose of 150 mg, until 36 weeks or until delivery. Aspirin was administered in the evening, taking into account the results of previous studies that demonstrated better efficacy when aspirin was administered before bedtime(27). In this study, aspirin decreased the risk of preterm preeclampsia by 62%, an effect that was later confirmed by a meta-analysis, but it had no effect on the risk of occurrence of term preeclampsia(17,28).

The ASPRE study data were used to evaluate the effects of aspirin in different subgroups of patients, in which the beneficial effects of aspirin were confirmed, with the exception of the subgroup with preexisting hypertension. This may be due to the fact that in the preexisting hypertension of the pregnancy there could already be a vascular damage with cardiovascular dysfunction(29). Studies on a large number of patients have demonstrated the safety of aspirin during pregnancy. Aspirin does not cause congenital defects, but also does not cause the arterial canal to close, thus excluding this theoretical risk(30-33). Aspirin was associated in one study with an increased risk of placental abruption, a risk that could be explained by the fact that aspirin treatment was initiated at an advanced gestational age(34). Other unwanted effects of aspirin that have been reported are postpartum hemorrhages and hemorrhagic events(35,36).


Preeclampsia remains one of the most significant medical complications of pregnancy, with substantial consequences for maternal and fetal health. In this context, screening for preeclampsia has become an essential component of prenatal care, allowing for early identification of women at a high risk of developing this condition. The algorithm proposed by the Fetal Medicine Foundation (FMF) in the first trimester has shown efficacy in the detection of women at risk for preeclampsia, particularly for early-onset forms, with a heightened risk for severe maternal-fetal complications. Implementing this algorithm nationwide could improve the pregnancy outcomes and reduce morbidity and mortality associated with preeclampsia. However, access to preeclampsia screening remains limited at present, being available only in certain medical centers with adequate infrastructure and resources. To ensure equitable prenatal care for all pregnant women, promotion and expansion of this service to a national level are necessary. In conclusion, first-trimester screening for preeclampsia should become a standard practice nationwide, and the administration of aspirin as a preventive measure should be advocated and used by all obstetricians to reduce the risk and enhance the maternal-fetal outcomes.

Corresponding author: Cristiana-Elena Durdu
E-mail: cristianadurdu@gmail.com


Conflict of interest: none declared.

financial support: none declared.

This work is permanently accessible online free of charge and published under the CC-BY licence.  



  1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785–99. 
  2. Tomimatsu T, Mimura K, Matsuzaki S, Endo M, Kumasawa K, Kimura T. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors. Int J Mol Sci. 2019;20(17):4246.
  3. Phumsiripaiboon P, Suksai M, Suntharasaj T, Geater A. Screening for pre-eclampsia: Performance of National Institute for Health and  Care Excellence guidelines versus American College of Obstetricians and Gynecologists recommendations. J Obstet Gynaecol Res. 2020;46(11):2323–31.
  4. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. Obstet Gynecol. 2018;132(1):e44–52. 
  5. Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–69. 
  6. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402–14. 
  7. Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome. Hypertens. 2020;75(4):918–26. 
  8. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83. 
  9. Lecarpentier E, Zsengellér ZK, Salahuddin S, et al. Total versus free placental growth factor levels in the pathogenesis of preeclampsia. Hypertens. 2020;76(3):875–83. 
  10. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121–31. 
  11. Agrawal S, Shinar S, Cerdeira AS, Redman C, Vatish M. Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women: a systematic review and meta-analysis. Hypertens. 2019;74(5):1124–35. 
  12. Stepan H, Herraiz I, Schlembach D, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45(3):241–6. 
  13. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005. 
  14. Jacobs M, Nassar N, Roberts CL, Hadfield R, Morris JM, Ashton AW. Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol. 2011;9:77. 
  15. Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014;34(7):618–27. 
  16. O’Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(6):756–60. 
  17. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22. 
  18. Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22. 
  19. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911–9. 
  20. Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hyperten. 2014;63(2):346–52. 
  21. Herraiz I, Simón E, Gómez-Arriaga PI, et al. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study. Pregnancy Hypertens. 2018;13:279–85. 
  22. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232–5. 
  23. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–8. 
  24. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366:l2381. 
  25. Konijnenberg A, Stokkers EW, van der Post JA, et al. Extensive platelet activation in preeclampsia compared with normal pregnancy:  enhanced expression of cell adhesion molecules. Am J Obstet Gynecol. 1997;176(2):461–9. 
  26. Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 2022;226(2S):S1108–19. 
  27. O’Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with Aspirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016;6(6):e011801. 
  28. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018;218(3):287-293.e1. 
  29. Poon LC, Wright D, Rolnik DL, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol. 2017;217(5):585.e1-585.e5. 
  30. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Aspirin and congenital malformations. Lancet. 1976;1(7974):1373–5. 
  31. Nørgård B, Puhó E, Czeizel AE, Skriver M V, Sørensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol. 2005;192(3):922–3. 
  32. Di Sessa TG, Moretti ML, Khoury A, Pulliam DA, Arheart KL, Sibai BM. Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol. 1994;171(4):892–900. 
  33. Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus-related to maternal pain medication?. 
  34. Z Geburtshilfe Neonatol. 2005;209(2):65–8. 
  35. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993;329(17):1213–8. 
  36. Mone F, Mulcahy C, McParland P, et al. Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ Open. 2018;8(7):e022056. 
  37. Subtil D, Goeusse P, Puech F, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG. 2003;110(5):475–84. 

Articole din ediţiile anterioare

GINECOLOGIE ONCOLOGICĂ | Ediţia 4 (2) / 2014

Screeningul primar în cancerul de col uterin - citologia cervico-vaginală vs detecţia tulpinilor HPV-HR

Octavian Munteanu, Luiza Rădulescu, Oana Bodean, Diana Cristina Secară, Monica Mihaela Cîrstoiu

Cancerul cervical ocupă al treilea loc din totalul cancerelor la femei în întreaga lume, cu peste 500.000 de cazuri noi diag­nosticate pe an, facto...

15 aprilie 2014
NEONATOLOGIE | Ediţia 14 (4) / 2016

Retinopatia de prematuritate - actualizare de screening şi management

Cerasela  Monica Alexiu, Prof. Dr. Elvira Brătilă, Mihai Mitran, Costin Berceanu, Simona Vlădăreanu

a dezvoltării vaselor sangvine retiniene la nou-născuţii prematuri. Este una din cele mai frecvente complicaţii ale prematurităţii, în special la p...

15 noiembrie 2016
GYNECOLOGY | Ediţia 3 33 / 2021

Actualizare asupra situării României în contextul recomandărilor Uniunii Europene privind screeningul cancerului genito-mamar

Roxana-Elena Bohîlţea, Corina  Grigoriu, Mihai Mitran, Ioniţă Ducu, Mihai Bianca Margareta, Costin Berceanu

La data de 2 decembrie 2003, în Jurnalul Oficial al Uniunii Europene, a fost publicată „Recomandarea Consiliului privind screeningul pentru cancer”...

28 septembrie 2021
GYNECOLOGY | Ediţia 3 33 / 2021

Analiza rezultatelor programelor naţionale de screening pentru depistarea activă precoce a cancerului de col uterin şi propunere de strategie

Coravu Violeta, Gh. Turcan, Natalia Ţurcan, Delia Grădinaru-Fometescu, Maria Sajin, Monica Mihaela Cîrstoiu

În cazul tuturor tipurilor de cancer, este universal valabil fap­tul că detectarea precoce îmbunătăţeşte semnificativ rata de supravieţuire.

28 septembrie 2021